18 results
8-K
LRMR
Larimar Therapeutics Inc
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
the lives of patients with rare disorders through innovative gene therapies. Mr. Thomas served as Chief Operating Officer and Chief Financial Officer
DEFM14A
LRMR
Larimar Therapeutics Inc
29 Apr 20
Proxy related to merger
3:20pm
the lives of patients with rare disorders through innovative gene therapies. Mr. Thomas served as Chief Operating Officer and Chief Financial Officer
PRER14A
7p9pq pwwr
10 Apr 20
Preliminary revised proxy
4:38pm
PREM14A
vqm48disemp
6 Mar 20
Preliminary proxy related to merger
5:32pm
8-K
EX-99.1
8qb 5oknl8ajy0cv9c
13 Jan 20
Regulation FD Disclosure
7:17am
DEFA14A
EX-99.1
hczjcfzo1uooi22un
13 Jan 20
Additional proxy soliciting materials
7:15am
DEFA14A
ot7g9bis
18 Dec 19
Additional proxy soliciting materials
4:31pm
8-K
EX-99.1
9ov1losm qp828
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
8-K
EX-99.2
ilg4pwj9wktvrl7b
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-99.2
jdjwhxr8
18 Dec 19
Additional proxy soliciting materials
8:11am
DEFA14A
EX-99.1
8uil72mcao8hwd rw4wy
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-99.1
8464n
17 Jan 19
Zafgen Announces Positive Results for Second Cohort
7:30am
8-K
EX-99.1
3mvj7o
25 Jun 18
Zafgen Announces Positive Full Results in Phase 2Proof-of-Concept Trial ofZGN-1061 in Patients withDifficult-to-Control Type 2 Diabetes
7:15am
8-K
EX-99.1
rb3ybjovpx
12 Jan 15
Other Events
12:00am
- Prev
- 1
- Next